The cardiometabolic drug rimonabant: after 2 years of RIO-Europe and STRADIVARIUS
- PMID: 18556715
- DOI: 10.1093/eurheartj/ehn255
The cardiometabolic drug rimonabant: after 2 years of RIO-Europe and STRADIVARIUS
Comment on
-
Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study.Eur Heart J. 2008 Jul;29(14):1761-71. doi: 10.1093/eurheartj/ehn076. Epub 2008 Apr 15. Eur Heart J. 2008. PMID: 18417461 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
